title: Enlarging the scope of managing benign prostatic hyperplasia: addressing sexual function and quality of life.
abstract: Benign prostatic hyperplasia is a common genitourinary disorder that increases in incidence with age. Symptoms of this condition include a weak urinary stream, hesitancy, intermittency and sensations of incomplete emptying, as well as frequency, urgency, urge incontinence and nocturia. These symptoms can be ameliorated successfully by a variety of medical treatments - such as alpha(1)-adrenergic blockade and 5-alpha-reductase inhibition - and surgical therapies - including transurethral resection of the prostate and less-invasive procedures. However, many of the treatments are known to result in sexual dysfunction, which can have a negative impact on the patient's quality of life. This must be considered when the physician seeks to determine the appropriate treatment for an individual patient. Current reports suggest that alpha(1)-adrenergic blockade is most likely to improve lower urinary tract symptoms while resulting in the fewest sexual side-effects; 5-alpha-reductase inhibitors appear to be particularly appropriate in men with large prostates. Among surgical therapies, transurethral resection of the prostate remains the gold standard, but is associated with a high incidence of sexual side-effects, especially retrograde ejaculation. Transurethral incision of the prostate, which is an endoscopic procedure, may be as effective as transurethral resection, but results in fewer side-effects. Minimally invasive procedures, including laser ablation or resection of the prostate, transurethral microwave thermotherapy and transurethral needle ablation, are rapidly evolving technologies that have demonstrated promising results, at least in the short term.
authors.affiliation: Department of Urology, Loyola University Medical Center, Stritch school of Medicine, Maywood, IL, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Martin
authors.forename: J P
authors.initials: JP
authors.lastname: Mulhall
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000368:Aged; D017115:Catheter Ablation; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000150:complications / Q000601:surgery*; D011788:Quality of Life; D020728:Transurethral Resection of Prostate / Q000009:adverse effects
chemical_list: D058891:5-alpha Reductase Inhibitors